Browse News
Filter News
Found 76 articles
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
4/16/2024
Endeavor BioMedicines today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success.
-
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
3/11/2024
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates during its virtual investor event.
-
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
3/7/2024
Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share.
-
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences - March 6, 2024
3/6/2024
Ventyx Biosciences, Inc. today announced that Company executives will participate in the following upcoming investor conferences.
-
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
3/4/2024
Ventyx Biosciences, Inc. today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m. ET.
-
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
2/27/2024
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.
-
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
2/22/2024
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced that data from the Phase 2 trial of VTX002 in ulcerative colitis will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 22, 2024, in Stockholm, Sweden.
-
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
-
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
12/13/2023
Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced the appointment of Jeff Albers as Chair of the Board and Allison Luo, M.D., to the Board of Directors.
-
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
11/27/2023
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc.
-
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
11/21/2023
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference.
-
Ventyx Biosciences to Participate in the 2023 Jefferies London Healthcare Conference
11/10/2023
Ventyx Biosciences, Inc. announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference.
-
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
11/9/2023
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress.
-
Although it hit primary and secondary endpoints in a Phase II study, Ventyx Biosciences concluded that the results weren’t strong enough to face the stiff competition for the indication.
-
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
11/6/2023
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a corporate update.
-
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
10/9/2023
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (UC).
-
Ventyx Biosciences to Participate in Two Upcoming September 2023 Investor Conferences
8/30/2023
Ventyx Biosciences, Inc. announced that Company executives will participate in the following upcoming investor conferences.
-
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
8/10/2023
Ventyx Biosciences, Inc. announced financial results for the second quarter ended June 30, 2023, and highlighted recent pipeline and business progress.
-
Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023
8/3/2023
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the second quarter ended June 30, 2023 after market close on August 10, 2023.